相关实验视频

Updated: Jun 4, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

关于Musa balbisiana不同部分的低血糖影响的比较研究

Thi Ngoc Nhon Hoang¹, Quang Liem Nguyen¹, Thi Thanh Ngan Le¹

¹Faculty of Food Science and Technology Ho chi Minh City University of Industry and Trade (HUIT) Ho Chi Minh City Vietnam.

Food science & nutrition

|December 26, 2024

概括

穆萨巴尔比西亚纳提取物显示出作为天然抗糖尿病剂的潜力. 它的种子表现出最强的消化酶抑制,并有效降低小鼠的血糖,表明治疗可能性.

科学领域:

药理学和植物化学
代谢障碍研究研究研究代谢障碍
自然产品药物发现药物发现

背景情况:

糖尿病是一种慢性代谢疾病,其特征是高血糖症.
传统医学经常利用各种植物部位来管理健康状况.
香 (Musa balbisiana) 在民间疗法中有着悠久的使用历史.

研究的目的:

为了研究不同Musa balbisiana部分的抗糖尿病潜力.
为了评估α-氨酶和α-葡萄糖酶的体外抑制.
评估在aloxan诱导的糖尿病小鼠中的体内低血糖效应.

主要方法:

在体外酶抑制测定α-氨酶和α-葡萄糖酶.
在体内研究,使用aloxan诱导的糖尿病小鼠模型.
从M.M.提取物的分析. 巴尔比西亚纳的花,伪茎,花朵,水果,皮和种子.

主要成果:

所有经过测试的M. balbisiana的部分表现出对α-amylase和α-glucosidase的抑制活性.
种子提取物对这两种酶具有最高的抑制能力 (α-氨酶IC50: fμg/mL,α-葡萄糖酶IC50: 21.63μg/mL).
果实,玉米和花朵提取物在体内表现出显著的低血糖效应.

结论:

Musa balbisiana的部分具有作为低血糖剂的天然来源的潜力.
种子提取物特别有希望,因为它具有强大的酶抑制和降血糖特性.
需要进一步的临床研究来证实功能性食品和药品中人类使用的安全性和有效性.

关键词:

穆萨·巴尔比西亚纳 (Musa balbisiana) 是一个美国人.血糖指数血糖指数血糖指数低血糖症是一种低血糖症.α-氨酸酶的使用 α-葡萄糖酸酶的使用.

更多相关视频

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...